Bloomberg Daybreak: Europe 06/10/2025
Bloomberg Daybreak Europe is your essential morning viewing to stay ahead. Live from London, we set the agenda for your day, catching you up with overnight markets news from the US and Asia. And we'll tell you what matters for investors in Europe, giving you insight before trading begins. Today's guests: Sunaina Sinha Haldea, Global Head of Private Capital Advisory at Raymond James & Rodrigo Liang, Co-founder and CEO of SambaNova Systems. (Source: Bloomberg)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
43 minutes ago
- Yahoo
Arista Networks (ANET) Stock Slides as Market Rises: Facts to Know Before You Trade
Arista Networks (ANET) ended the recent trading session at $93.70, demonstrating a -3.2% swing from the preceding day's closing price. This change lagged the S&P 500's daily gain of 0.55%. At the same time, the Dow added 0.25%, and the tech-heavy Nasdaq gained 0.63%. Heading into today, shares of the cloud networking company had gained 4.85% over the past month, lagging the Computer and Technology sector's gain of 11.3% and the S&P 500's gain of 6.29% in that time. Investors will be eagerly watching for the performance of Arista Networks in its upcoming earnings disclosure. The company's upcoming EPS is projected at $0.65, signifying a 25% increase compared to the same quarter of the previous year. Meanwhile, our latest consensus estimate is calling for revenue of $2.11 billion, up 24.67% from the prior-year quarter. In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $2.56 per share and a revenue of $8.31 billion, indicating changes of +12.78% and +18.72%, respectively, from the former year. Investors might also notice recent changes to analyst estimates for Arista Networks. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Hence, positive alterations in estimates signify analyst optimism regarding the company's business and profitability. Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model. The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. As of now, Arista Networks holds a Zacks Rank of #2 (Buy). Looking at its valuation, Arista Networks is holding a Forward P/E ratio of 37.83. This denotes a premium relative to the industry's average Forward P/E of 29.13. One should further note that ANET currently holds a PEG ratio of 2.56. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. By the end of yesterday's trading, the Internet - Software industry had an average PEG ratio of 2.33. The Internet - Software industry is part of the Computer and Technology sector. This group has a Zacks Industry Rank of 54, putting it in the top 22% of all 250+ industries. The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. To follow ANET in the coming trading sessions, be sure to utilize Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Arista Networks, Inc. (ANET) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Yahoo
43 minutes ago
- Yahoo
Freshpet (FRPT) Exceeds Market Returns: Some Facts to Consider
The latest trading session saw Freshpet (FRPT) ending at $78.89, denoting a +1.87% adjustment from its last day's close. The stock outperformed the S&P 500, which registered a daily gain of 0.55%. Elsewhere, the Dow saw an upswing of 0.25%, while the tech-heavy Nasdaq appreciated by 0.63%. Shares of the seller of refrigerated fresh pet food have depreciated by 2.74% over the course of the past month, underperforming the Consumer Staples sector's gain of 1.91% and the S&P 500's gain of 6.29%. The investment community will be paying close attention to the earnings performance of Freshpet in its upcoming release. The company is predicted to post an EPS of $0.11, indicating a 466.67% growth compared to the equivalent quarter last year. In the meantime, our current consensus estimate forecasts the revenue to be $268.8 million, indicating a 14.26% growth compared to the corresponding quarter of the prior year. FRPT's full-year Zacks Consensus Estimates are calling for earnings of $1.39 per share and revenue of $1.13 billion. These results would represent year-over-year changes of +80.52% and +15.88%, respectively. Investors should also take note of any recent adjustments to analyst estimates for Freshpet. These revisions typically reflect the latest short-term business trends, which can change frequently. Consequently, upward revisions in estimates express analysts' positivity towards the company's business operations and its ability to generate profits. Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system. The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.29% higher. Freshpet presently features a Zacks Rank of #3 (Hold). Looking at its valuation, Freshpet is holding a Forward P/E ratio of 55.81. For comparison, its industry has an average Forward P/E of 16.57, which means Freshpet is trading at a premium to the group. Investors should also note that FRPT has a PEG ratio of 1.17 right now. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The average PEG ratio for the Food - Miscellaneous industry stood at 1.67 at the close of the market yesterday. The Food - Miscellaneous industry is part of the Consumer Staples sector. This industry, currently bearing a Zacks Industry Rank of 165, finds itself in the bottom 33% echelons of all 250+ industries. The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Be sure to follow all of these stock-moving metrics, and many more, on Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Freshpet, Inc. (FRPT) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
43 minutes ago
- Yahoo
CRISPR Therapeutics AG (CRSP) Rises Higher Than Market: Key Facts
The latest trading session saw CRISPR Therapeutics AG (CRSP) ending at $42.94, denoting a +2.02% adjustment from its last day's close. The stock outperformed the S&P 500, which registered a daily gain of 0.55%. At the same time, the Dow added 0.25%, and the tech-heavy Nasdaq gained 0.63%. Shares of the company have appreciated by 11.97% over the course of the past month, outperforming the Medical sector's gain of 3.49% and the S&P 500's gain of 6.29%. Investors will be eagerly watching for the performance of CRISPR Therapeutics AG in its upcoming earnings disclosure. On that day, CRISPR Therapeutics AG is projected to report earnings of -$1.54 per share, which would represent a year-over-year decline of 3.36%. At the same time, our most recent consensus estimate is projecting a revenue of $5.89 million, reflecting a 1032.88% rise from the equivalent quarter last year. Regarding the entire year, the Zacks Consensus Estimates forecast earnings of -$5.54 per share and revenue of $39.95 million, indicating changes of -27.65% and +7.06%, respectively, compared to the previous year. It's also important for investors to be aware of any recent modifications to analyst estimates for CRISPR Therapeutics AG. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook. Our research shows that these estimate changes are directly correlated with near-term stock prices. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system. The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, there's been a 1.68% fall in the Zacks Consensus EPS estimate. CRISPR Therapeutics AG is currently a Zacks Rank #3 (Hold). The Medical - Biomedical and Genetics industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 76, placing it within the top 31% of over 250 industries. The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Be sure to use to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report CRISPR Therapeutics AG (CRSP) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
